MRK · News · 20260805N
Product / Drug Pipeline Progress
Merck & Co., Inc. · 2026-08-05 · Importance 31 · Surprise 42 · In source text
Merck advanced sac-TMT, an antibody-drug conjugate targeting Trop-2, into multiple Phase 3 cancer trials. The program is positioned as a potential future lung-cancer treatment and supports Merck’s effort to build growth beyond Keytruda. Pipeline activity also spans oncology, HIV, and immunology programs.
Key facts
- Merck highlighted advancement of sac-TMT (an ADC targeting Trop-2) into multiple Phase 3 cancer trials. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | Merck highlighted advancement of sac-TMT (an ADC targeting Trop-2) into multiple Phase 3 cancer trials. |